Roche Ltd.
Last updated on 2017-03-17T15:06+0300.
About this image
| Key Titles and Phrases | Count | Lang | Last Seen |
|---|
| Names | Lang | Count |
|---|---|---|
| Roche Ltd. | EN | 100.00% |
| Type | Entity Name | Count |
|---|---|---|
 | Roche Holding AG | 10.09% |
| Inc | 9.19% |
 | Thermo Fisher Scientific | 3.80% |
| Thermo Fisher Scientific Inc | 3.70% |
| Abbott Laboratories | 3.40% |
| Five Forces | 2.40% |
| Laura Wood | 2.40% |
| Agilent Technologies | 2.30% |
| Pfizer Inc | 2.20% |
| Novartis | 2.10% |
| SA | 2.10% |
| GlaxoSmithKline | 1.80% |
| World Health Organization | 1.70% |
| Ekke Primauno | 1.70% |
| Becton Dickinson | 1.60% |
| Siemens | 1.60% |
| Merck KGaA | 1.50% |
| Eli Lilly | 1.50% |
| Bristol Myers Squibb | 1.40% |
| Saudi | 1.20% |
| GlaxoSmithKline Plc | 1.10% |
| Table | 1.10% |
| Danaher Corporation | 1.00% |
| Pvt Ltd | 0.90% |
| Product Development | 0.90% |
| European Union | 0.90% |
| Teva Pharmaceuticals | 0.90% |
| Strategy | 0.80% |
| AstraZeneca PLC | 0.80% |
| Myriad Genetics | 0.80% |
| Type | Entity Name | Score |
|---|---|---|
| Roche Holding AG | 0.0968 |
| Thermo Fisher Scientific Inc | 0.0356 |
| Thermo Fisher Scientific | 0.0355 |
| Abbott Laboratories | 0.032 |
| Agilent Technologies | 0.0229 |
| Five Forces | 0.0226 |
| Novartis | 0.0199 |
| Laura Wood | 0.0198 |
| Becton Dickinson | 0.0162 |
| Siemens | 0.0158 |
| GlaxoSmithKline | 0.0156 |
| Merck KGaA | 0.0155 |
| Bristol Myers Squibb | 0.0141 |
| Eli Lilly | 0.0135 |
| Inc | 0.0123 |
| SA | 0.011 |
| GlaxoSmithKline Plc | 0.011 |
| Danaher Corporation | 0.01 |
| Product Development | 0.0094 |
| Table | 0.009 |
| Teva Pharmaceuticals | 0.0089 |
| Pvt Ltd | 0.0082 |
| AstraZeneca PLC | 0.0081 |
| Myriad Genetics | 0.008 |
| Quest Diagnostics | 0.0079 |
| Ekke Primauno | 0.0074 |
| Novo Nordisk | 0.0074 |
| General Electric | 0.0061 |
| Genentech Inc | 0.0061 |
| Roche Group | 0.006 |
Show/hide duplicate news articles.
Show/hide duplicate news articles.
Tools
Friday, August 12, 2022
2:29:00 AM EAT
Languages 
Select your languages
Explore Relations
Please send any comments or suggestions to 